Related Experiment Video
Updated: Jan 8, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013
Elsa Vitale1, Alessandro Rizzo2, Lorenza Maistrello3
1Directorate of Health Professions and Nursing, ASL, Bari, Italy.
Purpose:
To investigate the incidence of Infusion-Related Reactions (IRRs) among cancer patients receiving Immune Checkpoint Inhibitors (ICIs) and immune-based combinations.
Patients And Methods:
The ARON-MOUSEION-013 was registered in PROSPERO (CRD420251018433). Observational, randomized and quasi-experimental studies were included in the present review, and rates in IRR among cancer adults (≥18 years) receiving ICIs were recorded and then analyzed.
Results:
A total of 4 records were considered for analyses, with a total of 55 observations and 35 events. The overall prevalence of IRR, considering Any Grade, was 67.4% [95% CI: 3.9%; 99.1%]. Considering Grade ≥ 3, a total of 55 observations and 8 events were registered. The overall prevalence of irAEs in IRRs was 6% [95% CI: 0.2%; 74.7%].
Conclusion:
Mild-to-moderate IRRs are not rare events in patients receiving ICIs. IRRs may be avoided to manage these infusions slowly; however, severe reactions require emergency handling.
Related Concept Videos
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

